Transcatheter Pulmonary Artery Banding [PAB] for HFrEF: Two Year Follow Up and Invasive Exercise Hemodynamics From the Ongoing First-In-Human Trial

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker's Bureau - Abbott; Ancora Heart; Bristol-Myers Squibb; Impluse Dynamics; Medtronic; ADI; Nuwellis; Procyrion; Valgen Medtech; Restore Medical; Cordio; CareDx
• Equity/Stock(s)/Options - Transmedics